Syros Pharmaceuticals (NASDAQ:SYRS)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, March 14th. They currently have a $10.00 target price on the stock. HC Wainwright’s target price points to a potential downside of 19.55% from the stock’s previous close.
A number of other research firms also recently weighed in on SYRS. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. Oppenheimer set a $28.00 price target on Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, January 8th. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 price target on the stock. in a research note on Saturday, January 20th. Wedbush reiterated an “outperform” rating and set a $13.00 target price (up from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. Finally, BidaskClub upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.13.
Shares of NASDAQ SYRS traded up $0.03 during midday trading on Wednesday, reaching $12.43. The company had a trading volume of 148,091 shares, compared to its average volume of 184,092. Syros Pharmaceuticals has a one year low of $6.30 and a one year high of $24.38. The firm has a market cap of $399.20, a PE ratio of -5.84 and a beta of -2.83.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Monday, March 12th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). sell-side analysts anticipate that Syros Pharmaceuticals will post -2.22 earnings per share for the current year.
In other news, Director Srinivas Akkaraju acquired 209,424 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was purchased at an average price of $9.55 per share, for a total transaction of $1,999,999.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 33.60% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors grew its position in Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after acquiring an additional 5,016 shares in the last quarter. Bank of New York Mellon Corp grew its position in Syros Pharmaceuticals by 17.7% in the third quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock worth $520,000 after acquiring an additional 5,305 shares in the last quarter. New York State Common Retirement Fund grew its position in Syros Pharmaceuticals by 167.9% in the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after acquiring an additional 8,399 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Syros Pharmaceuticals in the third quarter worth about $133,000. Finally, Two Sigma Investments LP grew its position in Syros Pharmaceuticals by 80.3% in the fourth quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after acquiring an additional 9,439 shares in the last quarter. Institutional investors own 49.33% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Syros Pharmaceuticals (SYRS) Rating Reiterated by HC Wainwright” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/hc-wainwright-reiterates-hold-rating-for-syros-pharmaceuticals-syrs.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.